PMID- 8862279
OWN - NLM
STAT- MEDLINE
DCOM- 19961209
LR  - 20191024
IS  - 1077-9450 (Print)
IS  - 1077-9450 (Linking)
VI  - 13
IP  - 2
DP  - 1996 Oct 1
TI  - Infections associated with totally implantable venous access devices (TIVAD) in 
      human immunodeficiency virus-infected patients.
PG  - 146-54
AB  - We report on a retrospective study evaluating infectious morbidity associated 
      with totally implantable venous access devices (TIVAD) (Port-A-Cath) in 
      HIV-infected patients. This study of 84 consecutive HIV-infected patients 
      requiring 89 TIVAD between January 1990 and October 1993 was performed in the 
      Department of Infectious Diseases Hopital de l'Institut Pasteur, Paris, France. 
      The total number of catheter days was 11,595. Eighteen of 89 patients with TIVAD 
      (20%) were infected, causing 25 infectious events (25/89: 28%) among 17 different 
      patients (17/84: 20%). The infection rate was 0.22 per 100 catheter days. Mean 
      onset of infection was 82 days. Twenty microorganisms were isolated: 
      Staphylococcus aureus in eight cases (40%), coagulase-negative Staphylococcus in 
      six cases (30%), Streptococcus D faecalis in one case; Gram-negative bacilli were 
      found in five cases (25%). All patients received an intravenous antibiotherapy 
      combined with a local lock treatment in eight cases. Nine TIVAD removals were 
      performed. One death was related to the TIVAD infection. No additional 
      predisposing factor for infection was identified other than the implied condition 
      of the HIV infection. The population and material in this study were homogeneous. 
      The TIVAD infection rate was comparable to other published reports. Prospective 
      evaluation comparing tunneled catheter and TIVAD in HIV-infected patients is 
      needed.
FAU - Dega, H
AU  - Dega H
AD  - Department of Infectious Diseases, Hopital de l'Institut Pasteur, Paris, France.
FAU - Eliaszewicz, M
AU  - Eliaszewicz M
FAU - Gisselbrecht, M
AU  - Gisselbrecht M
FAU - Fleury, J
AU  - Fleury J
FAU - Pialoux, G
AU  - Pialoux G
FAU - Janssen, B
AU  - Janssen B
FAU - de Saint-Martin, L
AU  - de Saint-Martin L
FAU - Gonzalez-Canali, G
AU  - Gonzalez-Canali G
FAU - Dupont, B
AU  - Dupont B
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - J Acquir Immune Defic Syndr Hum Retrovirol
JT  - Journal of acquired immune deficiency syndromes and human retrovirology : 
      official publication of the International Retrovirology Association
JID - 9501482
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Bacteremia/*diagnosis/drug therapy/epidemiology/mortality
MH  - Catheterization, Central Venous/*adverse effects
MH  - Female
MH  - Follow-Up Studies
MH  - HIV Infections/*therapy
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Time Factors
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - 10.1097/00042560-199610010-00005 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Oct 1;13(2):146-54. doi: 
      10.1097/00042560-199610010-00005.